BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 38377196)

  • 1. Small-molecule inhibition of MAP2K4 is synergistic with RAS inhibitors in
    Jansen RA; Mainardi S; Dias MH; Bosma A; van Dijk E; Selig R; Albrecht W; Laufer SA; Zender L; Bernards R
    Proc Natl Acad Sci U S A; 2024 Feb; 121(9):e2319492121. PubMed ID: 38377196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS Inhibitor Resistance in
    Suzuki S; Yonesaka K; Teramura T; Takehara T; Kato R; Sakai H; Haratani K; Tanizaki J; Kawakami H; Hayashi H; Sakai K; Nishio K; Nakagawa K
    Clin Cancer Res; 2021 Oct; 27(20):5697-5707. PubMed ID: 34365406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A role for the unfolded protein response stress sensor ERN1 in regulating the response to MEK inhibitors in KRAS mutant colon cancers.
    Šuštić T; van Wageningen S; Bosdriesz E; Reid RJD; Dittmar J; Lieftink C; Beijersbergen RL; Wessels LFA; Rothstein R; Bernards R
    Genome Med; 2018 Nov; 10(1):90. PubMed ID: 30482246
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacological characteristics and clinical study results of the first RAS inhibitor sotorasib (LUMAKRAS
    Hoshiyama H
    Nihon Yakurigaku Zasshi; 2023; 158(5):391-398. PubMed ID: 37673617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C-Mutant Cancers.
    Khan HY; Nagasaka M; Li Y; Aboukameel A; Uddin MH; Sexton R; Bannoura S; Mzannar Y; Al-Hallak MN; Kim S; Beydoun R; Landesman Y; Mamdani H; Uprety D; Philip PA; Mohammad RM; Shields AF; Azmi AS
    Cancer Res Commun; 2022 May; 2(5):342-352. PubMed ID: 35573474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. From bench to bedside: current development and emerging trend of KRAS-targeted therapy.
    Chen Y; Liu QP; Xie H; Ding J
    Acta Pharmacol Sin; 2024 Apr; 45(4):686-703. PubMed ID: 38049578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sotorasib: a treatment for non-small cell lung cancer with the KRAS G12C mutation.
    Zheng X; Luo J; Liu W; Ashby CR; Chen ZS; Lin L
    Drugs Today (Barc); 2022 Apr; 58(4):175-185. PubMed ID: 35412531
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recent progress in targeting KRAS mutant cancers with covalent G12C-specific inhibitors.
    Rathod LS; Dabhade PS; Mokale SN
    Drug Discov Today; 2023 May; 28(5):103557. PubMed ID: 36934967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editorial: Recent Approval of Sotorasib as the First Targeted Therapy for KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer (NSCLC).
    Parums DV
    Med Sci Monit; 2022 Nov; 28():e938746. PubMed ID: 36317327
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS
    Li S; Liu S; Deng J; Akbay EA; Hai J; Ambrogio C; Zhang L; Zhou F; Jenkins RW; Adeegbe DO; Gao P; Wang X; Paweletz CP; Herter-Sprie GS; Chen T; Gutiérrez-Quiceno L; Zhang Y; Merlino AA; Quinn MM; Zeng Y; Yu X; Liu Y; Fan L; Aguirre AJ; Barbie DA; Yi X; Wong KK
    Clin Cancer Res; 2018 Oct; 24(19):4854-4864. PubMed ID: 29945997
    [No Abstract]   [Full Text] [Related]  

  • 11. BCL-X
    Khan S; Wiegand J; Zhang P; Hu W; Thummuri D; Budamagunta V; Hua N; Jin L; Allegra CJ; Kopetz SE; Zajac-Kaye M; Kaye FJ; Zheng G; Zhou D
    J Hematol Oncol; 2022 Mar; 15(1):23. PubMed ID: 35260176
    [TBL] [Abstract][Full Text] [Related]  

  • 12. More to the RAS Story: KRAS
    Lietman CD; Johnson ML; McCormick F; Lindsay CR
    Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-13. PubMed ID: 35561303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of
    Malhotra J; Nguyen D; Tan T; Semeniuk Iii GB
    Clin Adv Hematol Oncol; 2024 Mar; 22(2):67-75. PubMed ID: 38446474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting KRAS in non-small-cell lung cancer: recent progress and new approaches.
    Reck M; Carbone DP; Garassino M; Barlesi F
    Ann Oncol; 2021 Sep; 32(9):1101-1110. PubMed ID: 34089836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Kirsten rat sarcoma viral oncogene homolog G12C mutant advanced non-small-cell lung cancer treated with MEK1/2 inhibitor trametinib: a case report.
    Jiang Y; Liu X; Lv DL; Zhao XL
    Anticancer Drugs; 2022 Jan; 33(1):e752-e755. PubMed ID: 34387588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting Mutated KRAS Genes to Treat Solid Tumours.
    Krishnan T; Roberts-Thomson R; Broadbridge V; Price T
    Mol Diagn Ther; 2022 Jan; 26(1):39-49. PubMed ID: 34914038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AXL signal mediates adaptive resistance to KRAS G12C inhibitors in KRAS G12C-mutant tumor cells.
    Morimoto K; Yamada T; Hirai S; Katayama Y; Fukui S; Sawada R; Tachibana Y; Matsui Y; Nakamura R; Ishida M; Kawachi H; Kunimasa K; Sasaki T; Nishida M; Furuya N; Watanabe S; Shiotsu S; Nishioka N; Horinaka M; Sakai T; Uehara H; Yano S; Son BK; Tokuda S; Takayama K
    Cancer Lett; 2024 Apr; 587():216692. PubMed ID: 38342232
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Acquired Resistance to KRAS
    Tanaka N; Lin JJ; Li C; Ryan MB; Zhang J; Kiedrowski LA; Michel AG; Syed MU; Fella KA; Sakhi M; Baiev I; Juric D; Gainor JF; Klempner SJ; Lennerz JK; Siravegna G; Bar-Peled L; Hata AN; Heist RS; Corcoran RB
    Cancer Discov; 2021 Aug; 11(8):1913-1922. PubMed ID: 33824136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.
    Cheema PK; Banerji SO; Blais N; Chu QS; Juergens RA; Leighl NB; Sacher A; Sheffield BS; Snow S; Vincent M; Wheatley-Price PF; Yip S; Melosky BL
    Curr Oncol; 2023 Jul; 30(7):6473-6496. PubMed ID: 37504336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MEK inhibitor and anti-EGFR antibody overcome sotorasib resistance signals and enhance its antitumor effect in colorectal cancer cells.
    Hondo N; Kitazawa M; Koyama M; Nakamura S; Tokumaru S; Miyazaki S; Kataoka M; Seharada K; Soejima Y
    Cancer Lett; 2023 Jul; 567():216264. PubMed ID: 37336286
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.